Does the thymus influence the effectiveness of cancer immunotherapies?

A major breakthrough in understanding cancer treatments reveals that the state of the thymus plays a key role in the success of immunotherapies. This organ, often overlooked in adults, is essential for the maturation of T lymphocytes, immune cells that target tumors. A recent study shows that patients with a healthier thymus respond better to immunotherapies, regardless of the type of cancer.

Researchers analyzed more than 3,400 patients with various cancers, including lung, melanoma, and kidney cancers. Using an artificial intelligence method applied to thoracic scans, they assessed thymus health. The results indicate that individuals with a more active thymus have a reduced risk of disease progression and prolonged survival. This relationship persists even when accounting for other markers such as tumor mutational burden or PD-L1 protein expression, which are often used to predict treatment response.

The thymus produces naive T lymphocytes, which are essential for a diverse immune response. In patients with good thymic health, there is a greater variety of T cell receptors in the blood and tumors, a sign of a more robust immune system. Conversely, a weakened thymus, often linked to age or previous treatments, limits this defensive capacity.

This discovery suggests that assessing thymic health could become a standard tool for personalizing treatments. It also paves the way for strategies aimed at regenerating the thymus, thereby improving the effectiveness of immunotherapies. Unlike current biomarkers, which focus on the tumor, this approach considers the patient’s overall condition, offering a more comprehensive view of the fight against cancer.

Site Sources

Official Study Source

DOI: https://doi.org/10.1038/s41586-026-10243-x

Title: Thymic health and immunotherapy outcomes in patients with cancer

Journal: Nature

Publisher: Springer Science and Business Media LLC

Authors: Simon Bernatz; Vasco Prudente; Suraj Pai; Asbjørn K. Attermann; Alessandro Di Federico; Andrew Rowan; Selvaraju Veeriah; Lars Dyrskjøt; Leonard Nürnberg; Joao V. Alessi; Patrick A. Ott; Elad Sharon; Allan Hackshaw; Nicholas McGranahan; Christopher Abbosh; Raymond H. Mak; Danielle Bitterman; Mark Awad; Biagio Ricciuti; Charles Swanton; Mariam Jamal-Hanjani; Nicolai J. Birkbak; Hugo J. W. L. Aerts